150 related articles for article (PubMed ID: 21225621)
1. Inhibition of ovarian cancer by RGD-P125A-endostatin-Fc fusion proteins.
Jing Y; Lu H; Wu K; Subramanian IV; Ramakrishnan S
Int J Cancer; 2011 Aug; 129(3):751-61. PubMed ID: 21225621
[TBL] [Abstract][Full Text] [Related]
2. Addition of integrin binding sequence to a mutant human endostatin improves inhibition of tumor growth.
Yokoyama Y; Ramakrishnan S
Int J Cancer; 2004 Oct; 111(6):839-48. PubMed ID: 15300795
[TBL] [Abstract][Full Text] [Related]
3. Targeted delivery of an antibody-mutant human endostatin fusion protein results in enhanced antitumor efficacy.
Shin SU; Cho HM; Merchan J; Zhang J; Kovacs K; Jing Y; Ramakrishnan S; Rosenblatt JD
Mol Cancer Ther; 2011 Apr; 10(4):603-14. PubMed ID: 21393427
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Vasculogenic Mimicry and Angiogenesis by an Anti-EGFR IgG1-Human Endostatin-P125A Fusion Protein Reduces Triple Negative Breast Cancer Metastases.
Shin SU; Cho HM; Das R; Gil-Henn H; Ramakrishnan S; Al Bayati A; Carroll SF; Zhang Y; Sankar AP; Elledge C; Pimentel A; Blonska M; Rosenblatt JD
Cells; 2021 Oct; 10(11):. PubMed ID: 34831127
[TBL] [Abstract][Full Text] [Related]
5. Improved biological activity of a mutant endostatin containing a single amino-acid substitution.
Yokoyama Y; Ramakrishnan S
Br J Cancer; 2004 Apr; 90(8):1627-35. PubMed ID: 15083196
[TBL] [Abstract][Full Text] [Related]
6. Addition of an aminopeptidase N-binding sequence to human endostatin improves inhibition of ovarian carcinoma growth.
Yokoyama Y; Ramakrishnan S
Cancer; 2005 Jul; 104(2):321-31. PubMed ID: 15952188
[TBL] [Abstract][Full Text] [Related]
7. Linking antibody Fc domain to endostatin significantly improves endostatin half-life and efficacy.
Lee TY; Tjin Tham Sjin RM; Movahedi S; Ahmed B; Pravda EA; Lo KM; Gillies SD; Folkman J; Javaherian K
Clin Cancer Res; 2008 Mar; 14(5):1487-93. PubMed ID: 18316573
[TBL] [Abstract][Full Text] [Related]
8. Enhanced inhibition of murine tumor and human breast tumor xenografts using targeted delivery of an antibody-endostatin fusion protein.
Cho HM; Rosenblatt JD; Kang YS; Iruela-Arispe ML; Morrison SL; Penichet ML; Kwon YG; Kim TW; Webster KA; Nechustan H; Shin SU
Mol Cancer Ther; 2005 Jun; 4(6):956-67. PubMed ID: 15956253
[TBL] [Abstract][Full Text] [Related]
9. Genetically engineered endostatin-lidamycin fusion proteins effectively inhibit tumor growth and metastasis.
Jiang WG; Lu XA; Shang BY; Fu Y; Zhang SH; Zhou D; Li L; Li Y; Luo Y; Zhen YS
BMC Cancer; 2013 Oct; 13():479. PubMed ID: 24128285
[TBL] [Abstract][Full Text] [Related]
10. Anti-Tumor Activity and Pharmacokinetics of AP25-Fc Fusion Protein.
Pei D; Hu J; Rao C; Yu P; Xu H; Wang J
Int J Med Sci; 2019; 16(7):1032-1041. PubMed ID: 31341417
[TBL] [Abstract][Full Text] [Related]
11. Adeno-associated virus-mediated delivery of a mutant endostatin suppresses ovarian carcinoma growth in mice.
Subramanian IV; Ghebre R; Ramakrishnan S
Gene Ther; 2005 Jan; 12(1):30-8. PubMed ID: 15550927
[TBL] [Abstract][Full Text] [Related]
12. AAV-P125A-endostatin and paclitaxel treatment increases endoreduplication in endothelial cells and inhibits metastasis of breast cancer.
Subramanian IV; Devineni S; Ghebre R; Ghosh G; Joshi HP; Jing Y; Truskinovsky AM; Ramakrishnan S
Gene Ther; 2011 Feb; 18(2):145-54. PubMed ID: 20844568
[TBL] [Abstract][Full Text] [Related]
13. Adeno-associated virus-mediated delivery of a mutant endostatin in combination with carboplatin treatment inhibits orthotopic growth of ovarian cancer and improves long-term survival.
Subramanian IV; Bui Nguyen TM; Truskinovsky AM; Tolar J; Blazar BR; Ramakrishnan S
Cancer Res; 2006 Apr; 66(8):4319-28. PubMed ID: 16618757
[TBL] [Abstract][Full Text] [Related]
14. A tumor-penetrating peptide modification enhances the antitumor activity of endostatin in vivo.
Hai-Tao Z; Hui-Cheng L; Zheng-Wu L; Chang-Hong G
Anticancer Drugs; 2011 Jun; 22(5):409-15. PubMed ID: 21427563
[TBL] [Abstract][Full Text] [Related]
15. [Combining bevacizumab with endostatin gets better antitumor efficacy in vivo in lung cancer animal model].
Niu N; Li B; Liu C; Hu Y; Li X; Li J; Shi H; Zhang H
Zhongguo Fei Ai Za Zhi; 2013 Feb; 16(2):61-6. PubMed ID: 23425896
[TBL] [Abstract][Full Text] [Related]
16. Extension of the in vivo half-life of endostatin and its improved anti-tumor activities upon fusion to a humanized antibody against tumor-associated glycoprotein 72 in a mouse model of human colorectal carcinoma.
Lee SH; Jeung IC; Park TW; Lee K; Lee DG; Cho YL; Lee TS; Na HJ; Park YJ; Lee HG; Jeong MS; Bae KH; Lee SC; Lee HJ; Kwon YG; Hong HJ; Kim JS; Min JK
Oncotarget; 2015 Mar; 6(9):7182-94. PubMed ID: 25762629
[TBL] [Abstract][Full Text] [Related]
17. Antibody-Drug Conjugate αEGFR-E-P125A Reduces Triple-negative Breast Cancer Vasculogenic Mimicry, Motility, and Metastasis through Inhibition of EGFR, Integrin, and FAK/STAT3 Signaling.
Sankar AP; Cho HM; Shin SU; Sneh T; Ramakrishnan S; Elledge C; Zhang Y; Das R; Gil-Henn H; Rosenblatt JD
Cancer Res Commun; 2024 Mar; 4(3):738-756. PubMed ID: 38315147
[TBL] [Abstract][Full Text] [Related]
18. Dual targeting of tumor angiogenesis and chemotherapy by endostatin-cytosine deaminase-uracil phosphoribosyltransferase.
Chen CT; Yamaguchi H; Lee HJ; Du Y; Lee HH; Xia W; Yu WH; Hsu JL; Yen CJ; Sun HL; Wang Y; Yeh ET; Hortobagyi GN; Hung MC
Mol Cancer Ther; 2011 Aug; 10(8):1327-36. PubMed ID: 21610170
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic targeting of angiogenesis with a recombinant CTT peptide-endostatin mimic-kringle 5 protein.
Wang H; Yang Z; Gu J
Mol Cancer Ther; 2014 Nov; 13(11):2674-87. PubMed ID: 25127900
[TBL] [Abstract][Full Text] [Related]
20. Binding of endostatin to human ovarian cancer cells inhibits cell attachment.
Yokoyama Y; Ramakrishnan S
Int J Cancer; 2007 Dec; 121(11):2402-9. PubMed ID: 17597104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
